Overview of phosphodiesterase 5 inhibition in erectile dysfunction (Q35580624)

9 August 2017

1 reference

title

Overview of phosphodiesterase 5 inhibition in erectile dysfunction (English)

1 reference

9 August 2017

Raymond C Rosen

1

1 reference

PubMed ID

14609619

9 August 2017

John B Kostis

series ordinal

2

1 reference

PubMed ID

14609619

9 August 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

American Journal of Cardiology

9 August 2017

1 reference

9 August 2017

92

1 reference

9 August 2017

9M-18M

1 reference

9 August 2017

9A

1 reference

Cyclic GMP phosphodiesterase-5: target of sildenafil

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Physiology of erection and pharmacological management of impotence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Cyclic nucleotide phosphodiesterases: relating structure and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Phosphodiesterase 5 inhibitors and nitrergic transmission-from zaprinast to sildenafil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

A new era in the treatment of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Overall cardiovascular profile of sildenafil citrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Sildenafil in patients with cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Cardiovascular effects of tadalafil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Cardiovascular effects of tadalafil in patients on common antihypertensive therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Effects of tadalafil on erectile dysfunction in men with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900824-5

10.1016/S0002-9149(03)00824-5

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14609619